TNDM241220C28000
- 4.40
- 0.000.00%
Tandem Diabetes Care Newsroom
Morgan Stanley Maintains Tandem Diabetes Care(TNDM.US) With Hold Rating, Maintains Target Price $45
Analysts Have Conflicting Sentiments on These Healthcare Companies: Waters (WAT), Pharvaris (PHVS) and Tandem Diabetes Care (TNDM)
Barclays Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Raises Target Price to $60
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $40 to $75
Tandem Diabetes Care Is Maintained at Buy by Canaccord Genuity
Baird Maintains Neutral on Tandem Diabetes Care, Lowers Price Target to $37
Tandem Diabetes Care Analyst Ratings
A Quick Look at Today's Ratings for Tandem Diabetes Care(TNDM.US), With a Forecast Between $37 to $65
RBC Capital Remains a Buy on Tandem Diabetes Care (TNDM)
Bernstein Initiates Tandem Diabetes Care(TNDM.US) With Buy Rating, Announces Target Price $42
Stifel Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $60
Tandem Diabetes Care: Hold Rating Reiterated Amidst Market Challenges and Slow Product Uptake
RBC Capital Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $65
Tandem Diabetes Care Analyst Ratings
Goldman Sachs Initiates Tandem Diabetes Care(TNDM.US) With Hold Rating, Announces Target Price $46
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Tandem Diabetes Care (TNDM) and BioMarin Pharmaceutical (BMRN)
RBC Capital Initiates Tandem Diabetes Care(TNDM.US) With Buy Rating, Announces Target Price $65
Citi Maintains Tandem Diabetes Care(TNDM.US) With Buy Rating, Maintains Target Price $57
Tandem Diabetes Care Analyst Ratings
Morgan Stanley Maintains Equal-Weight on Tandem Diabetes Care, Maintains $45 Price Target